Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.45 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 2/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL193208 | 1.00 | NPSR1 (0.47) | NPSR1TYRALDH1A1SMN1; SMN2PLA2G2A | |
| SCHEMBL1952824 | 1.00 | NPSR1 (0.47) | NPSR1TYRALDH1A1SMN1; SMN2PLA2G2A | |
| Hydrochloric Acid SCHEMBL27540646 | 0.98 | NPSR1 (0.46) | NPSR1TYRALDH1A1SMN1; SMN2PLA2G2A | |
| SCHEMBL17011234 | 0.86 | TYR (0.42) | TYRALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL28870475 | 0.86 | TYR (0.42) | TYRALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL6443671 | 0.85 | SMN1; SMN2 (0.47) | NPSR1TYRALDH1A1SMN1; SMN2PLA2G2A | |
| Hydrochloric Acid SCHEMBL27630841 | 0.85 | CTSL (0.40) | NPSR1TYRALDH1A1SMN1; SMN2MMP12 | |
| SCHEMBL6443665 | 0.85 | SMN1; SMN2 (0.47) | NPSR1TYRALDH1A1SMN1; SMN2PLA2G2A | |
| SCHEMBL16927642 | 0.85 | ALDH1A1 (0.58) | TYRALDH1A1LMNAATM | |
| SCHEMBL18686187 | 0.84 | CA12 (0.47) | NPSR1ALDH1A1SMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3438106-A1 | ANTI-VIRAL COMPOUNDS | AbbVie Ireland Unlimited Company (IE) | 2019-02-06 | — | — | EP | claimed |
| US-20190015402-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2019-01-17 | — | — | US | claimed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| EP-4119539-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2023-01-18 | — | — | EP | disclosed |
| EP-4119539-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2023-01-18 | — | — | EP | disclosed |
| EP-3353145-B1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPHARMA LTD (KY) | 2022-09-28 | — | — | EP | disclosed |
| CN-113061089-A | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2021-07-02 | — | — | CN | disclosed |
| US-20210130281-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2021-05-06 | — | — | US | disclosed |
| US-20210130281-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2021-05-06 | — | — | US | disclosed |
| CN-108283000-B | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2021-04-13 | — | — | CN | disclosed |
| US-10941107-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | XW LABORATORIES INC. (KY) | 2021-03-09 | — | — | US | disclosed |
| US-5663200-A | CARBAMOYL PEPTIDE DERIVATIVES AS VIRICIDES | CIBA-GEIGY CORPORATION (US) | 1997-09-02 | — | — | US | disclosed |
| US-5587388-A | AIDS; VIRICIDES | LUCKY LIMITED (KR) | 1996-12-24 | — | — | US | disclosed |
| EP-0604368-B1 | Anti retroviral hydrazine derivatives | CIBA GEIGY AG (CH) | 1996-09-18 | — | — | EP | disclosed |
| EP-0708085-A2 | Antiviral ethers of aspartate protease substrate isosteres | CIBA-GEIGY AG (CH) | 1996-04-24 | — | — | EP | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
| EP-0601486-A1 | Cis-epoxide derivatives useful as irreversible HIV protease inhibitors and process and intermediates for their preparation | LUCKY LTD. (KR) | 1994-06-15 | — | — | EP | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10941107-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | GABRB2, GABRB3, GABRB1 | NPSR1 1973/4885TYR 3256/4885ALDH1A1 869/4885 |
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | NPSR1 4296/4885TYR 3103/4885ALDH1A1 2858/4885 |
| US-20190015402-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | NPSR1 4296/4885TYR 3103/4885ALDH1A1 2858/4885 |
| US-20210130281-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB2, GABRB3, GABRB1 | NPSR1 1973/4885TYR 3256/4885ALDH1A1 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.